Procurement Trends, Indications, and Outcomes of Heart–Lung Transplantation in the Contemporary Era
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15447 ↗At a glance
Journal article in Clinical Transplantation, 2024. Written by John A Treffalls and 10 co-authors. Institution: Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Tissue and Organ Procurement, Heart-Lung Transplantation, Tissue Donors. Cited 5 times so far (Crossref); 23 references.
Abstract (original language)
Background
Evolving trends in organ procurement and technological innovation prompted an investigation into recent trends, indications, and outcomes following combined heart–lung transplantation (HLTx).
Methods
The United Network for Organ Sharing database was queried for all adult (≥18 years) HLTx performed between July 1, 2013 and June 30, 2023. Patients with previous transplants were excluded. The primary endpoint was the effect of donor, recipient, and transplantation characteristics on 1‐ and 5‐year survival. Secondary analyses included a comparison of HLTx at high‐ and low‐volume centers, an assessment of HLTx following donation after circulatory death (DCD), and an evaluation of HLTx volume over time. Cox proportional‐hazards models were used to assess factors associated with mortality. Temporal trends were evaluated with linear regression.
Results
After exclusions, 319 patients were analyzed, of whom 5 (1.6%) were DCD. HLTx volume increased from 2013 to 2023 ( p < 0.001). One‐ and 5‐year survival following HLTx was 84.0% and 59.5%, respectively. One‐year survival was higher for patients undergoing HLTx at a high‐volume center (88.3% vs. 77.9%; p = 0.012). After risk adjustment, extracorporeal membrane oxygenation support 72 h posttransplant and predischarge dialysis were associated with increased 1‐year mortality (HR = 3.19, 95% CI = 1.86–5.49 and HR = 3.47, 95% CI = 2.17–5.54, respectively) and 5‐year mortality (HR = 2.901, 95% CI = 1.679–5.011 and HR = 3.327, 95% CI = 2.085–5.311, respectively), but HLTx at a high‐volume center was not associated with either.
Conclusions
HLTx volume has resurged, with DCD HLTx emerging as a viable procurement strategy. Factors associated with 1‐ and 5‐year survival may be used to guide postoperative management following HLTx.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
- College of Medicine, University of Florida, Gainesville, Florida, USA.
- Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Division of Pulmonary and Critical Care, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
ORCID profiles: John A Treffalls, Qiudong Chen, Kelly Pennington, Philip J Spencer
Cite
APA
Treffalls, J. A., Bilgili, A., Brennan, Z., Sharaf, O. M., Griffeth, E. M., Chen, Q., Pennington, K., Spencer, P. J., Villavicencio, M. A., Daly, R. C., & Saddoughi, S. A. (2024). Procurement Trends, Indications, and Outcomes of Heart–Lung Transplantation in the Contemporary Era. Clinical Transplantation. https://doi.org/10.1111/ctr.15447
Vancouver
Treffalls JA, Bilgili A, Brennan Z, Sharaf OM, Griffeth EM, Chen Q, et al. Procurement Trends, Indications, and Outcomes of Heart–Lung Transplantation in the Contemporary Era. Clinical Transplantation. 2024. doi:10.1111/ctr.15447
BibTeX
@article{Treffalls2024,
author = {Treffalls, John A and Bilgili, Ahmet and Brennan, Zachary and Sharaf, Omar M and Griffeth, Elaine M and Chen, Qiudong and Pennington, Kelly and Spencer, Philip J and Villavicencio, Mauricio A and Daly, Richard C and Saddoughi, Sahar A},
title = {Procurement Trends, Indications, and Outcomes of Heart–Lung Transplantation in the Contemporary Era},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15447}
}
EUVIMED